Over 2,000 patients have been treated worldwide with Kuros Biosciences' MagnetOs bone graft, an alternative to the gold standard treatment of autograft. The product launched in the U.K. in 2017.
MagnetOs' submicron surface structure, applied during manufacturing, is designed to direct early wound healing toward a bone-forming pathway to support predictable healing and reliable fusion.
Joost de Bruijn, Chief Executive Officer of Kuros, said: “MagnetOs has been developed on a foundation of decades of collective orthobiologics research and product development from our team at Kuros and has demonstrated outstanding qualities as a bone graft. Having seen the development of MagnetOs from concept through to clinical practice, the 2,000-patient milestone marks a historic moment for our team. We look forward to seeing many more surgeons and their patients benefiting from the unique properties of MagnetOs in the years to come.”